Phase Ib Trial of Afatinib and BI 836845 in Advanced Non-Small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Park, Keunchil [1 ]
Lin, Chia-Chi [2 ]
Huang, Dennis Chin-Lun [3 ]
Shin, Heather Hye-Jung [4 ]
Bogenrieder, Thomas [5 ]
Tan, Daniel S. -W. [6 ]
机构：
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Hematol Oncol, Seoul, South Korea
[2] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[3] Boehringer Ingelheim Taiwan Ltd, Taipei, Taiwan
[4] Boehringer Ingelheim Korea, Seoul, South Korea
[5] Boehringer Ingelheim Rcv, Vienna, Austria
[6] Natl Canc Ctr, Dept Med Oncol, Singapore, Singapore
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
Monoclonal antibody; IGF; Phase; 1; NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.01-100
引用
收藏
页码：S554 / S555
页数：2
相关论文
共 50 条
  • [31] A phase II trial of denileukin difititox- in previously treated, advanced non-small cell lung cancer (NSCLC).
    Lewis, MAG
    Shukla, R
    Kleykamp, B
    Jazieh, AR
    Hainsworth, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 689S - 689S
  • [32] A phase II trial of weekly cisplatin and docetaxel in advanced non-small cell lung cancer (NSCLC)-Final report
    Sovak, M. A.
    Guensch, L.
    Joyce, P.
    Lutzker, S. G.
    Schwartz, S.
    Shih, W. J.
    Zheng, L.
    Aisner, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [33] A Randomized Phase III Clinical Trial of Anlotinib Hydrochloride in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
    Han, Baohui
    Li, Kai
    Zhao, Yizhuo
    Wang, Qiming
    Zhang, Li
    Shi, Jianhua
    Wang, Zhehai
    He, Jianxing
    Shi, Yuankai
    Cheng, Yin
    Chen, Weiqiang
    Wang, Xiuwen
    Luo, Yi
    Nan, Kejun
    Jin, Faguang
    Dong, Jian
    Li, Baolan
    Zhou, Jianying
    Chen, Yinlan
    Wang, Donglin
    Zhou, Xin
    Yu, Yan
    Chen, Liming
    Liu, Anwen
    Huang, Jianjin
    Huang, Cheng
    Cao, Bangwei
    Chen, Jun
    Ma, Rui
    Yu, Zhuang
    Ding, Cuimin
    Wang, Hongbing
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S886 - S887
  • [34] A phase II trial of weekly paclitaxel and carboplatin for elderly patients with advanced non-small cell lung cancer (NSCLC).
    Usui, K
    Inoue, A
    Ishimoto, O
    Tanaka, M
    Koinumaru, S
    Matsubara, N
    Kanbe, M
    Gomi, K
    Saijo, Y
    Nukiwa, T
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 682S - 682S
  • [35] Phase II trial of concurrent erlotinib in locally advanced non-small cell lung cancer (LA-NSCLC)
    Hansen, O.
    Knap, M.
    Khalil, A.
    Nyhus, C.
    Brink, C.
    Hoffmann, L.
    Schytte, T.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S663 - S663
  • [36] A phase II trial of denileukin diftitox in patients with previously treated advanced non-small cell lung cancer (NSCLC).
    Lewis, MAG
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 653S - 653S
  • [37] Biweekly carboplatin and gemcitabine for untreated advanced non-small cell lung cancer (NSCLC). A multicenter phase II trial
    Domine, M
    Gomez, RG
    Firvida, J
    Delgado, J
    Estevez, L
    Docampo, LI
    Leon, A
    Pachon, V
    Casado, V
    Lobo, F
    LUNG CANCER, 2005, 49 : S242 - S242
  • [38] Phase Ib study of sintilimab in combination with chemotherapy for 1L advanced or metastatic non-small cell lung cancer (NSCLC).
    Xu, Nong
    Ying, Kejing
    Wang, Ziping
    Liu, Yunpeng
    Jiang, Haiping
    Zhou, Hui
    Wang, Shuyan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [39] AFATINIB IN MANAGEMENT OF NON-SMALL CELL LUNG CANCER (NSCLC): WHAT IS EVIDENCE SO FAR?
    Lin, L.
    Josephine, M.
    RESPIROLOGY, 2014, 19 : 38 - 38
  • [40] Phase 2 study of bortezomib±docetaxel in advanced non-small cell lung cancer (NSCLC)
    Fanucchi, M
    Fossella, F
    Fidias, P
    Natale, R
    Belt, R
    Govindan, R
    Raez, L
    Schiller, J
    Kashala, O
    Kelly, K
    LUNG CANCER, 2005, 49 : S30 - S30
12345